Glycopyrrolate, a quaternary ammonium anticholinergic compound, and atropine were evaluated in combination with neostigmine for antagonism of non-depolarizing neuromuscular block. A total of 641 patients were investigated in a "true-to-life" situation. The patients receiving glycopyrrolate with neostigmine had smaller changes in heart rate than those who received atropine. This was particularly apparent in patients with cardiovascular disease.
kg" 1 or glycopyrrolate 0.01 mg kg" 1 from coded ampoules using a double-blind technique. Allocation to either drug was random. Heart rate from the radial pulse and arterial pressure obtained by the Riva Rocci method were measured immediately before administration of the mixture and at 1, 2, 3, 4, 5, 7 and 10 min after, and thereafter at 5-min intervals up to the 40th minute. Subsequently, the measurements were made at 15-min intervals until 115 min. At each time, the anaesthetist's subjective assessment of salivation (unacceptably moist, moist, dry) and degree of reversal (incomplete, adequate, complete) were also recorded on simple three-point scales.
If, at any time, the quality of antagonism was judged by the investigator to be inadequate, or if severe muscarinic side-effects occurred, further doses of the mixture, atropine or neostigmine, were administered.
Data were recorded on specially designed computercompatible forms. Relevant patient information and details of all drugs and the doses used in the periods before, during and after the operation were recorded. If any patient required atropine during the period of observation, the data following the time of administration were excluded.
Student's t test was used for parametric analyses and either Fisher's exact test or the chi-squared test for non-parametric data.
RESULTS
The study was carried out over a 6-month period during which satisfactory data were obtained from 641 patients. The relevant details are shown in Thiopentone was used for induction of anaesthesia in 91% of the patients. Of the 71% of patients who received i.v. analgesia during operation, 53% were given fentanyl, while a variety of other narcotics was administered to the remaining patients. All received nitrous oxide and about two-thirds an additional inhalation agent. Of these patients, 87% received halothane.
The premedicant drugs and neuromuscular blockers used in the study are summarized in table II. There was no statistically significant difference between the two groups in respect of the distribution of drugs used before and during operation.
In the entire population, following the injection of the atropine-containing mixture, there was a significant increase in heart rate, but within 3 min there was a sustained and significant decrease in heart rate. However, the mixture with glycopyrrolate produced a significant but smaller initial increase in heart rate and the subsequent reduction in heart rate was less than that following atropine. The differences between the two groups were statistically significant at most times up to 40 min following injection of the drugs under study.
Because of the significant differences between the groups of patients with pre-existing heart disease, such as angina pectoris, hypertension, murmurs, myocardial infarction, and because of the importance of heart rate changes in such patients, it was considered necessary to analyse the data from these patients separately. These patients were well matched with regard to physical characteristics, premedication and therapy during operation. Figure 1 summarizes the heart rate results in this sub-group. The differences between the atropine group and the glycopyn-olate group are more marked than those in the patients without heart disease ( fig. 2 ). In the patients with heart disease, the use of neostigmine and atropine was followed by a statistically significant difference between initial and subsequent heart rates, except at the 3rd and 4th min after injection. In contrast, in the glycopyrrolate group a significant difference from initial values was noted only in the first 4 min following injection; no significant slowing of the heart rate was noted at any time. Statistically significant differences were noted between the heart rates of patients treated with atropine and those treated with glycopyrrolate.
In addition to the analysis of heart rate data by parametric methods, the frequency of clinically important bradycardia was studied; this was taken as a heart rate less than 60 beat min"
1 . In patients with pre-existing heart disease, a significant difference between the groups was noted at the 10th min, 23% in the atropine group and 4% in the glycopyrrolate group (P<0.05) ( fig. 3 ). There was a greater proportion of patients with bradycardia in the atropine group at other times, although the differences were not statistically significant. There was no statistically significant difference in the completeness of antagonism between the groups at any time.
The proportion of patients with a negligible amount of oral secretions following the administration of neostigmine was significantly greater in the first 3 min after injection when glycopyrrolate was used as the antichoUnergic (P< 0.012 to P<0.05). Because of inadequate antagonism, a second dose of the neostigmine-containing mixture was required in 4% of all patients.
An additional dose of atropine was given to 51 patients because of bradycardia. The proportion requiring atropine did not differ significantly between those who received atropine (8.9%) and those receiving glycopyrrolate (6.1%). However, in the atropine group, the median time following the administration of the reversal mixture at which supplementary atropine was given was 10 min, whereas in the glycopyrrolate group this occurred at 26 min. A second dose of atropine was given to 21% of the patients with heart disease who had received atropine with neostigmine, compared with 8.6% in the glycopyrrolate group; these differences were not statistically significant.
Changes in both systolic and diastolic arterial pressure were noted in both groups, but these were well within accepted clinical limits. No statistically significant alterations of heart rate were seen in those patients who had received fentanyl, pancuronium, halothane or gallamine.
DISCUSSION
Antagonism of a myoneural blocking drug with a combination of glycopyrrolate and neostigmine produced a different pattern of cardiovascular response than that produced by atropine and neostigmine. The initial tachycardia which followed injection of the mixtures was less in patients receiving glycopyrrolate, as was the subsequent decrease in heart rate. The overall finding was of a more stable cardiovascular system following reversal using glycopyrrolate. These results are in broad agreement with the findings of other workers (Ramamurthy, Shaker and Winnie, 1972; Klingenmaier et al., 1972; Mirakhur, Dundee and Clarke, 1977; Ostheimer, 1977) , although in a group of 20 patients Mirakhur, Dundee and Clarke (1977) failed to demonstrate an initial increase in heart rate following antagonism with neostigmine 2.5 mg and glycopyrrolate 0.5 mg-the same ratio of drugs as that used in the present study. This difference may be explained on the basis of a body weight-related dose of 0.01 mg kg" 1 in the present study and a smaller mean dose of 0.0076 mg kg" 1 in the study of Mirakhur, Dundee and Clarke (1977) .
It may be argued that the changes in heart rate noted here are not of clinical importance in patients with normal cardiovascular status. However, they may be important in patients with pre-existing heart disease. Our analyses demonstrated that, in such patients, administration of atropine with neostigmine produced wide and sudden changes in heart rate. In contrast, patients in the glycopyrrolate group maintained a more stable heart rate. Thus glycopyrrolate may be preferable to atropine in these subjects.
The quaternary nature of the ammonium group makes glycopyrrolate a compound which is completely ionized; this results in a slower onset of activity. It becomes apparent, therefore, that both neostigmine and glycopyrrolate have similar onset times of activity, thereby reducing the risk of increase in heart rate so often seen when neostigmine is given with atropine.
In those few patients who required an additional antichohnergic agent (atropine) to counteract excessive bradycardia, this was needed much later when glycopyrrolate was used as compared with atropine. This agrees with earlier work which showed that glycopyrrolate has a long duration of anticholinergic action (Wyant and Kao, 1974; Mirakhur, Dundee and Jones, 1978) .
In retrospect, we should have recorded the cardiac medication taken by patients. However, the resting heart rate in the cardiac sub-group was not significantly less than in the non-cardiac patients. This suggests that beta-blockers, for example, did not have a marked effect on our results.
The greater proportion of patients with an acceptable degree of oral secretions in the glycopyrrolate group confirms the potent anti-sialogogue activity of this compound (Wyant and Kao, 1974) .
In the present study, the dose of neostigmine was 0.05 mg kg" 1 and that of atropine, 0.02 mg kg-1 : a ratio of 2.5 : 1. It is not uncommon to use a fixed dose of neostigmine 2.5 mg and atropine 1.2 mg, a ratio of 2:1. Although one might attempt to explain the bradycardia on the basis of insufficient atropine, Mirakhur, Dundee and Clarke (1977) showed a similar response in heart rate when the neostigmine/atropine ratio was 2:1.
It is interesting to note that, although there was no control of patient selection, anaesthetic and surgical techniques and immediate postoperative care of our patients, the results from this "true-to-life" study produced data comparable to that from the initial carefully controlled investigations. This type of evaluation of new drugs might be attempted, when possible, to assess better their therapeutic and toxicological spectrum when used under clinical conditions.
It appears that antagonism of the non-depolarizing neuromuscular block using a combination of glycopyrrolate and neostigmine has advantages over the traditional combination of atropine and neostigmine. This advantage might be of particular value to those patients with cardiovascular disease. A more detailed study of such patients is necessary.
